XL 1p32/1q21

Amplification/Deletion Probe

Order Number
Package Size
100 µl


XL 1p32/1q21

This product has been replaced by XL CDKN2C/CKS1B. Order Number D-5099-100-OG TEST

Clinical Details

Multiple myeloma (MM) is a plasma cell malignancy characterized by very complex cytogenetic and molecular genetic aberrations. Hyperdiploid karyotypes are characterized mainly by trisomies of chromosomes 3, 5, 7, 9, 11, 15,19, and 21, non-hyperdiploid karytoypes typically have translocations involving the IGH locus at 14q32. The most frequent deletions are 13q, 17p and 1p32.

Deletions of chromosome 1p have been described in 7 % to 15 % of cases of myeloma with inconsistent clinical consequences. CDKN2C at 1p32.3 has been identified in myeloma cell lines as the potential target of the deletion. Gain of 1q is one of the most recurrent chromosomal aberrations in MM. Amplification and overexpression of the CKS1B gene in chromosome band 1q21 has been associated with an aggressive clinical course in multiple myeloma.

Clinical Applications

  • Multiple Myeloma and Plasma Cell Neoplasms (MM)


XL 1p32/1q21

XL 1p32/1q21 was hybridized to normal lymphocytes. The green labeled probe hybridizes to 1p32 and the orange signals are seen at 1q21. The interphase displays two orange and two green signals.

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and three orange (3O) signals, indicating a duplication of the CKS1B locus.

Expected Pattern 3

Aberrant Cell (typical results):
One green (1G) and two orange (2O) signals, indicating a deletion of the CDKN2C locus.


  • Shaugnessy, J (2005) Hematology 10:117-126
  • Leone et al (2008) Clin Cancer Res 14:6033-6041
  • Broyl et al (2010) Blood 116:2543-2553


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.